Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06017921
PHASE4

Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA

Sponsor: University of Sao Paulo General Hospital

View on ClinicalTrials.gov

Summary

The comorbidity between obstructive sleep apnea (OSA) and insomnia (COMISA) is common, and associated with poorer sleep quality. CPAP adherence among COMISA patients is worst than among those with OSA only. The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on adherence to CPAP after 30 days and after 6 months.

Official title: Effect of Eszopiclone on Adherence to Continuous Positive Airway Pressure (CPAP) and Severity of Insomnia in Patients With Comorbidity Between Insomnia and Obstructive Sleep Apnea (COMISA)

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2023-08-24

Completion Date

2026-03-20

Last Updated

2026-05-29

Healthy Volunteers

Yes

Interventions

DRUG

Eszopiclone 3 mg

Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm

DRUG

Placebo

Patients starting CPAP treatment will be randomized to either Eszopiclone or Placebo arm

Locations (1)

Sleep Laboratory, Heart Institute, Pulmonary Division, Hospital das Clínicas da Universidade de São Paulo

São Paulo, Brazil